Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

or REMS, program. People taking Spravato can only do so at clinics or medical offices certified to distribute it, and only under direct medical supervision. Still, Spravato’s expansion into a ...

My practice is a REMS-certified Spravato treatment center. Spravato is an FDA-approved formulation of ketamine for treatment-resistant depression. I love practicing interventional psychiatry with ...

My practice is a REMS-certified Spravato treatment center. Spravato is an FDA-approved formulation of ketamine for treatment-resistant depression. I love practicing interventional psychiatry with ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

Spravato is the first monotherapy for adults with major depressive disorder who had an inadequate response to at least two oral antidepressants. It is available only through a restricted REMS program.

TITUSVILLE, N.J., Jan. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA ...